Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo-Eric Persson

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Asian Journal of Andrology|August 21, 2012
Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et alBo-Eric Persson
European Urology|February 18, 2005
Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84Philip Weston, Bo-Eric Persson
European Urology|April 29, 2014
Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026E David Crawford, Bo-Eric Persson
Expert Review of Anticancer Therapy|December 4, 2009
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancerLaurent Boccon-Gibod, Peter Iversen, Bo-Eric Persson
The Journal of Urology|October 2, 2012
Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607E David Crawford, Joel Eisner, Bo-Eric Persson
Urology|December 3, 2014
Reply by the authorsE David Crawford, Bo-Eric Persson, Laurence Klotz
Therapeutic Advances in Urology|July 11, 2015
Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)Kurt Miller, Gabriele Simson, Sandra Goble, et al.
Neuroendocrinology|July 16, 2009
Degarelix: a new approach for the treatment of prostate cancerBo-Eric Persson, Tine Kold Olesen, Jens-Kristian Jensen
Therapeutic Advances in Urology|September 10, 2011
An update on the use of gonadotropin-releasing hormone antagonists in prostate cancerLaurent Boccon-Gibod, Egbert van der Meulen, Bo-Eric Persson
Trends in Endocrinology and Metabolism: TEM|November 15, 2008
Will GnRH antagonists improve prostate cancer treatment?Ilpo Huhtaniemi, Richard White, Craig A McArdle, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Asian Journal of Andrology|August 21, 2012
Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et alBo-Eric Persson
European Urology|February 18, 2005
Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84Philip Weston, Bo-Eric Persson
European Urology|April 29, 2014
Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026E David Crawford, Bo-Eric Persson
Expert Review of Anticancer Therapy|December 4, 2009
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancerLaurent Boccon-Gibod, Peter Iversen, Bo-Eric Persson
The Journal of Urology|October 2, 2012
Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607E David Crawford, Joel Eisner, Bo-Eric Persson
Urology|December 3, 2014
Reply by the authorsE David Crawford, Bo-Eric Persson, Laurence Klotz
Therapeutic Advances in Urology|July 11, 2015
Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)Kurt Miller, Gabriele Simson, Sandra Goble, et al.
Neuroendocrinology|July 16, 2009
Degarelix: a new approach for the treatment of prostate cancerBo-Eric Persson, Tine Kold Olesen, Jens-Kristian Jensen
Therapeutic Advances in Urology|September 10, 2011
An update on the use of gonadotropin-releasing hormone antagonists in prostate cancerLaurent Boccon-Gibod, Egbert van der Meulen, Bo-Eric Persson
Trends in Endocrinology and Metabolism: TEM|November 15, 2008
Will GnRH antagonists improve prostate cancer treatment?Ilpo Huhtaniemi, Richard White, Craig A McArdle, et al.
Pageof 3